We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




DNA Health Monitoring Campaign Launched

By LabMedica International staff writers
Posted on 11 Feb 2014
Print article
A DNA health test aims to assist in prevention of diseases associated with DNA damage and poor DNA repair.

The Berkeley-based startup, Exogen Biotechnology (CA, USA), has launched a unique citizen science campaign on Indiegogo, a global “crowd funding” website (San Francisco, CA, USA). The campaign is based on a laboratory test, which measures DNA breaks, the most lethal type of DNA damage and a potentially key indicator for overall health conditions. Launched on January 25, 2013, the project raised USD 20,000 in “crowd funding” within its first three days.

The technology measures physical breaks in the DNA of cells, which commonly result from an individual's lifestyle, environmental toxins, or personal genetics. The startup from the Lawrence Berkeley National Laboratory envisions that its DNA health monitoring technology will one day be as commonplace as a cholesterol test. The DNA health test aims to assist in prevention of diseases associated with DNA damage and poor DNA repair.

Exogen is allowing the public to assist in funding its large-scale citizen scientist project as well as gain access to the technology that is not yet available to the public. Supporters receive a kit that allows funders to safely collect three blood samples via sterile finger pricks. Blood samples are then mailed to Exogen’s proprietary research lab and analyzed either as a one-time event or on a regular basis throughout the year. The blood is processed for DNA damage and the results are made available back to the funder, securely and privately via a protected web application.

The core team behind the project is comprised of Dr. Sylvain Costes and Dr. Jonathan Tang, who are experts in understanding the link between ionizing radiation, DNA damage, and cancer induction. They developed this leading-edge technology over the past 10 years at the Lawrence Berkeley National Laboratory.

Dr. Tang commented, “Breaks in our DNA occur frequently, and our bodies repair them every day. However, as we age, the efficiency of how our bodies repair DNA breaks seems to weaken. This decline in repair efficiency can lead to accumulation of unrepaired DNA or misrepaired DNA, which may result in unpredictable and potentially lethal genetic mutations. Exogen hopes that monitoring DNA for breaks will allow individuals to assess the impact of various lifestyles and environments on their overall health and aging.”

Related Links:

Exogen Biotechnology


New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.